It's been a long time since I've heard the words "love" and "Amgen" in one sentence, but that's the approach the Los Angeles Times took in covering Wall Street's enthusiastic response to D-mab's performance in a recent clinical trial [1]. Oppenheimer's Bret Holley says the drug is on track to break the billion-dollar mark in 2010 [2] with an approval possible in 2009. And that helped send shares of Amgen surging to a 14-month high.
- reaad the story [3] from the Los Angeles Times
Related Articles:
Denosumab--Next gen biotech blockbusters [2]
Amgen shares buoyed by late-stage D-mab data [1]
Amgen's D-mab posts positive in late-stage trial [4]
Amgen's D-mab meets trial goal [5]
Denosumab: Amgen's salvation? [6]
Links:
[1] http://www.fiercebiotech.com/story/amgen-shares-buoyed-late-stage-denosumab-data/2008-07-28
[2] http://www.fiercebiotech.com/special-reports/denosumab-next-gen-biotech-blockbusters
[3] http://latimesblogs.latimes.com/money_co/2008/07/there-should-be.html
[4] http://www.fiercebiotech.com/story/amgen-s-d-mab-posts-positive-in-late-stage-trial/2008-04-03
[5] http://www.fiercebiotech.com/story/amgens-d-mab-meets-trial-goal/2008-01-25
[6] http://www.fiercebiotech.com/story/denosumab-amgens-salvation/2007-12-14